{
    "clinical_study": {
        "@rank": "126059", 
        "acronym": "ASPIRE", 
        "arm_group": {
            "arm_group_label": "AeroForm Tissue Expansion", 
            "arm_group_type": "Experimental", 
            "description": "AeroForm Breast Tissue Expander placed after mastectomy"
        }, 
        "brief_summary": {
            "textblock": "This study is intended to support previous positive results of the AeroForm\u2122 Patient\n      Controlled Tissue Expander System for breast reconstruction"
        }, 
        "brief_title": "Study of AeroForm Tissue Expander for Breast Reconstruction", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Breast Cancer", 
            "Breast Reconstruction"
        ], 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The objective of this study is to provide performance and safety data to support the\n      clinical use of the AeroForm\u2122 Patient Controlled Tissue Expander System for breast\n      reconstruction in a patient population with a broad selection criteria"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is female between the ages of 18 - 70.\n\n          2. Subject has elected two stage breast reconstruction with tissue expanders.\n\n          3. Subject's tissue is amenable to tissue expansion.\n\n          4. Subject is able to provide written informed consent.\n\n          5. Subject is able and willing to comply with all of the study requirements.\n\n          6. Subject has the physical, perceptual and cognitive capacity to understand and manage\n             the at home dosing regimen.\n\n        Exclusion Criteria:\n\n          1. Subject has residual gross malignancy following mastectomy.\n\n          2. Subject has a current infection at the intended expansion site.\n\n          3. Subject has clinically significant radiation fibrosis at the expansion site.\n\n          4. Subject has planned radiation at the intended expansion site during the time the\n             expander is implanted.\n\n          5. Subject has any co-morbid condition determined by the Investigator to place the\n             subject at an increased risk of complications (e.g., severe collagen vascular\n             disease, poorly managed diabetes).\n\n          6. Subject is currently participating in a concurrent investigational drug or device\n             study.\n\n          7. Subject is a current tobacco smoker.\n\n          8. Subject is overweight with a BMI > 33.\n\n          9. Subject has currently implanted electronic device such as a pacemaker, defibrillator,\n             neurostimulator device, or drug infusion device.\n\n         10. Subject is pregnant or planning to become pregnant during the study period.\n\n         11. Subject has a history of psychological condition, drug or alcohol misuse which may\n             interfere with their ability to use the device safely.\n\n             -"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01903174", 
            "org_study_id": "CTP-0004"
        }, 
        "intervention": {
            "arm_group_label": "AeroForm Tissue Expansion", 
            "description": "Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide", 
            "intervention_name": "AeroForm Breast Tissue Expander", 
            "intervention_type": "Device", 
            "other_name": [
                "AeroForm", 
                "AeroForm Tissue Expander", 
                "AeroForm Breast Tissue Expander", 
                "AirXpander", 
                "AirXpander Tissue Expander", 
                "AirXpanders Breast Tissue Expander"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Breast Reconstruction", 
            "Breast Tissue Expansion", 
            "Breast Tissue Expander", 
            "Two Stage Breast Reconstruction"
        ], 
        "lastchanged_date": "March 21, 2014", 
        "link": {
            "description": "AirXpanders Inc.", 
            "url": "http://www.airxpanders.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Subiaco", 
                    "country": "Australia", 
                    "state": "Western Australia", 
                    "zip": "6008"
                }, 
                "name": "Mount Hospital"
            }
        }, 
        "location_countries": {
            "country": "Australia"
        }, 
        "number_of_arms": "1", 
        "official_title": "AeroForm Patient Controlled Tissue Expansion for Breast Reconstruction", 
        "overall_official": {
            "affiliation": "Mount Hospital", 
            "last_name": "Tony Connell, F.R.A.C.S.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Australia: Transportation Good Authority (TGA)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Successful Tissue Expansion and Exchange to Permanent Breast Implant unless Precluded by a Non-Device Related Event", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01903174"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Adverse Events related to the Breast Reconstruction Procedure", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "AirXpanders, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AirXpanders, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}